The treatment of multiple myeloma (MM) has gone through several major advances over the last 5 years with the introduction of next generation proteasome inhibitors (PI; carfilzomib, ixazomib) and immunomodulatory derivatives (IMiD; pomalidomide), with these new agents having a substantial impact on patient outcome. However, despite these advances, MM remains a highly resistant disease given its propensity for clonal heterogeneity and its complex interaction with the surrounding bone marrow microenvironment. Almost all patients eventually relapse despite therapeutic responses to a PI, IMiD or both. With the regulatory approval of the monoclonal antibodies Daratumumab and Elotuzumab in 2015, impressive and durable responses are being observed, even in heavily pre-treated patients who have exhausted other therapeutic options, suggesting immunological approaches in this setting have real merit. This review will focus on newer monoclonal antibodies and chimericantigen receptor (CAR) T cell strategies currently under investigation and in various stages of clinical development.
Multiple myeloma (MM) is a clonal plasma cell disorder that results in the excess production of a monoclonal protein in the serum and/or urine leading to end organ damage, clinically categorized as CRAB: Hyper Calcaemia, Renal failure, Anaemia, and/or lytic Bone lesions. Unfortunately, MM targets the elderly and frail, making treatment of this serious disease very challenging. At the time of diagnosis, not all patients are eligible or willing to undergo high-dose melphalan and stem cell transplantation (HDM/SCT), an aggressive form of therapy that has been shown to prolong progressionfree (PFS) and overall survival (OS) in this disease. For patients who are not eligible for HDM/SCT, myeloma experts must rely on other anti-plasma cell approaches, which include alkylator agents (cyclophosphamide, oral melphalan), immunomodulators (IMiDs) (thalidomide, lenalidomide, pomalidomide) and proteasome inhibitors (PIs) (bortezomib, carfilzomib, ixazomib) . Triplet combinations of these agents have proven to be quite effective with manageable toxicity profiles overall. Over the last few years, the treatment algorithm for MM has undergone a major overhaul with the introduction of humanized monoclonal antibodies (mAbs). Daratumumab and elotuzumab are mAbs that effectively target CD38 and signalling lymphocytic activation family 7 (SLAMF7) on the surface of plasma cells, respectively, and have been approved by the US Food and Drug Administration (FDA) for the treatment of relapsed refractory disease as of 2015. Response rates observed with some of these agents have been impressive, even among double-refractory patients and those who harbour high-risk cytogenetics.
Immunotherapeutic strategies offer a new and exciting approach to target key molecular pathways that continue to be implicated in the survival of malignant plasma cells (Bae et al, 2014; Rosenblatt et al, 2014) . These targets include cell surface proteins [CD38, CD138 (SDC1), B cell maturation antigen (BCMA, TNFRSF17)], cytokines that play a role in plasma cell survival and proliferation [interleukin 6 (IL6) and B cell activating factor], signal regulators of bone metabolism [RANKL (TNFSF11), DKK1] and regulators of the immune system [PD-1(PDCD1), PD-L1(CD274)]. This review will focus on new mAbs and related innovative immunotherapeutic modalities currently under investigation and in various stages of evaluation as part of clinical trials (Table I) . Whilst vaccines in various stages of development are also considered highly promising, especially in smouldering disease and after initial therapy, these are considered beyond the scope of this review, and are addressed elsewhere. endothelium and promotes associations with surface molecules found on lymphocytes and natural killer cells (Funaro et al, 1993; Dianzani et al, 1994) . CD38 is overexpressed on the surface of clonal plasma cells (Lin et al, 2004) . The role of CD38 and its high expression on myeloma cells have made it an attractive target for treatment.
Isatuximab (SAR650984)
Similar to daratumumab (DARA), SAR650984 is a new generation humanized IgG1 mAb capable of targeting the CD38 receptor of clonal plasma cells. What differentiates isatuximab from DARA is its ability to specifically target a unique epitope on the CD38 surface protein. In preclinical studies, Deckert et al (2014) examined the activity of SAR650984 on lymphoma, leukaemia and MM cell lines and MM xenograft models in immune-deficient mice. This agent demonstrated strong pro-apoptotic activity in addition to complementdependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). As CD38 can be expressed on a wide range of haematopoietic cells, Feng et al (2017) wanted to study the effects of isatuximab on immune cells by examining CD38 levels in regulatory T cells (Tregs) from normal donors and from MM patients. Peripheral blood mononuclear cells were then treated with isatuximab with or without an IMiD (lenalidomide or pomalidomide) in order to determine the impact on the percentage and immunosuppressive activity of Tregs on conventional T cells. CD38 expression was higher on Tregs than on conventional T cells from MM patients versus normal donors. The expression of CD38 on Tregs was increased by lenalidomide and pomalidomide. Not only did isatuximab preferentially decrease Tregs and increase conventional T cell levels, but it also augmented MM cell lysis by CD8+ T cells and Natural Killer (NK) cells, thus restoring immune effector function against MM (Feng et al, 2017) . Overall, SAR650984 was validated as a functional CD38-targeting antibody (Deckert et al, 2014) .
Phase I/II
NCT01749969 was a phase 1b, open-label, dose escalation study examining the safety and efficacy of isatuximab administered in 2 dosing schedules (3, 5, 10 mg/kg every other week or 10, 20 mg/kg weekly for 4 weeks then every other week thereafter) in combination with lenalidomide 25 mg days 1-21 and dexamethasone 40 mg weekly in a relapsedrefractory MM (RRMM) population. Eighty-two per cent of patients were refractory to previous lenalidomide therapy and 68% had received pomalidomide or carfilzomib. Patients were continued on study drug until disease progression, unacceptable adverse events (AEs) or physician/patient preference. Bilateral pneumonia in the 20 mg/kg cohort was the only grade 3 dose-limiting toxicity (DLT) to be reported. The maximum tolerated dose (MTD) was not reached.
Infusion reactions were reported in 56% of the participants (grade 1/2 in 84% of patients), of which 88% occurred during the first infusion. Besides infusion-related reactions (IRR), the most common treatment-emergent AEs (TEAEs, all grades) were diarrhoea (53%), fatigue (49%), upper respiratory infections (40%) and nausea (35%). The overall response rate (ORR) was 56%, similar between the 10 mg/kg every other week and the 10 and 20 mg/kg weekly/every other week cohorts. The ORR did not differ, even among lenalidomide-refractory patients (ORR 51%) and the median progression-free survival (mPFS) was 8Á5 months (Martin et al, 2017 ).
An open label, phase Ib study, combining isatuximab with pomalidomide and dexamethasone in patients with RRMM, is currently recruiting patients (NCT02283775). Preliminary results are available on 14 patients: 8 patients treated at 5 mg/kg and 6 patients treated at 10 mg/kg . The most frequent treatment-related AEs were fatigue (64%), upper respiratory tract infection, tremor, dyspnoea and cough (29% each). IRRs occurred in 8 (57%) patients; all cases were minor (grade 1/2). Of the 13 evaluable patients, 8/13 (62%) achieved at least a partial response (PR) and 10/13 (77%) at least a minimal response (MR). Given these encouraging results, a phase III trial to evaluate isatuximab with pomalidomide and dexamethasone is now underway (NCT02990338) ( Table I) .
In a phase Ib dose escalation-trial (NCT02332850), combining isatuximab with carfilzomib in the RRMM population, preliminary data was available for 10 patients for presentation at the ASH Annual Meeting in 2016 (Martin et al, 2016) . Isatuximab was given weekly or every 2 weeks in combination with carfilzomib at standard doses. The ORR was 80%, with 2 very good partial responses (VGPRs) and 6 PRs for a clinical benefit rate of 90%. Haematological toxicity was mild with grade 3/4 anaemia (9%), grade 3/4 neutropenia (9%) and grade 3/4 lymphopenia (64%). The most serious adverse event was a grade 3 pneumonia (18%). About half the patients experienced mild (grade 1 or 2) infusion reactions. Expanded accrual is ongoing for this study (Martin et al, 2016) .
Other ongoing studies include isatuximab in high-risk smouldering MM (NCT02960555), and isatuximab combined with various backbone regimens [RVD (lenalidomide-bortezomib-dexamethasone) and CYBORD (cyclophosphamidebortezomib-dexamethasone)] in newly diagnosed patients who are ineligible for SCT (NCT02513186).
MOR202
MOR202 is a human anti-CD38 mAb that exerts its antitumour effect via ADCC and ADCP. In vitro studies have compared the ADCC profile of MOR202 on MM cells and normal haematopoietic cells with respect to daratumumab and isatuximab (Boxhammer et al, 2015) . Overall, the in vitro studies demonstrated equivalent killing compared to other anti-CD38 antibodies except in normal haematopoietic cells (expressing low levels of CD38), where the ability MOR202 to do so was significantly reduced. The combination of MOR202 with lenalidomide, bortezomib or melphalan was able to drastically reduce bone lysis as well as significantly reduce (>90%) the M protein levels. All mice that received MOR202 alone eventually died from disease progression. Conversely, when MOR202 was combined with bortezomib or lenalidomide, approximately 40% of mice were free of MM at day 98 (study termination) (Boxhammer et al, 2015) .
In an ongoing Phase I/IIa, multicentre study, MOR202 is being administered as monotherapy or in combination with dexamethasone, pomalidomide-dexamethasone and lenalidomide-dexamethasone to patients with RRMM (Raab et al, 2016) . Preliminary data were presented at the American Society of Hematology conference in 2016. Sixty-six patients have been treated with MOR202 (Raab et al, 2016) : 18 patients receiving MOR202 alone, 8 receiving MOR202 and lenalidomide, and 5 receiving MOR202 and pomalidomide. The treatment-emergent AEs were similar to those reported with other CD38 mAbs, which include: anaemia, fatigue, IRRs and leucopenia. Grade 3 or greater AEs were reported in 64% of patients. IRRs occurred in only 3/31 (10%) patients, all low grade (≤2) and during the first infusion. In this trial, the MTD has not been reached. There have not been any treatment-related deaths. Of the 16 evaluable patients in the MOR202 alone arm, there were 3 PRs (19%) and 2 VGPRs (13%). Three of5 patients responded to the MOR202 and pomalidomide, including 2 complete responses (CRs) with a median time to response of 4 weeks, indicating encouraging preliminary activity, although the data remain early and require further follow up, with efficacy analysis ongoing (Table I) .
Anti-CD138
CD138 is a protein expressed on the surface of myeloma cells as well as on normal plasma cells but at lower levels (Wijdenes et al, 1996) . CD138 acts as a co-receptor for MM growth factors and also mediates cell adhesion (Dhodapkar et al, 1998) .
Indatuximab Ravtansine (BT062)
BT062 is composed of a chimerized anti-CD138 mAb conjugated to a cytotoxic agent in the form of maytansinoid (DM4). Once BT062 is bound to its ligand, the conjugate is internalized by the target cell and DM4 is released, resulting in cell death. In vitro studies have demonstrated significant inhibition of cell growth and adhesion of MM cells to bone marrow stromal cells (Ikeda et al, 2009) . Other preclinical studies have demonstrated synergy when lenalidomide or bortezomib were combined with BT062 resulting in enhanced cytotoxicity (Zuber et al, 2010) .
A dose-escalation, open-label, multicentre, Phase I clinical trial was conducted; 32 patients previously treated with an IMiD and PI received one of 7 dose levels ranging from 10 mg/m 2 to 200 mg/m 2 . The MTD was defined at 200 mg/ m 2 , with mucositis as the DLT. Among the 27 evaluable patients, 1 patient had a PR and 2 patients had MRs. Stable disease (SD) was noted in an additional 11 patients. Most patients came off study due to disease progression (Jagannath et al, 2011) . In another Phase I/II study, BT062 was administered for 3 weeks out of a 4-week cycle. Fifty-two per cent of patients experienced at least SD with an acceptable toxicity profile (90% of the AEs were grade 1-2) (Table I) (Heffner et al, 2012) . A phase I/IIa, open-label, multicentre study evaluating the safety and efficacy of BT062 combined with lenalidomide and dexamethasone was initiated. Increasing doses of BT062 (days 1, 8 and 15, every 4 weeks) in combination with lenalidomide (25 mg on days 1-21) and low dose dexamethasone (40 mg weekly) were administered to patients with RRMM. A total of 45 patients were included in the analysis and had received BT062 at doses of 80 mg/m 2 (n = 3), 100 mg/m 2 (n = 36) or 120 mg/m 2 (n = 6) at the cut-off date. At the highest dose level, grade 3 mucositis in one patient and grade 3 anaemia in another patient were observed and considered as DLTs. The MTD was defined as 100 mg/m 2 and was selected for the recommended phase II dosing. Eighty-nine per cent of the reported AEs were grade 1 or 2 and they included fatigue, hypokalaemia, and diarrhoea. Among the 36 evaluable patients, the ORR was 78% across all doses: stringent CR (sCR, n = 1), CR (n = 2), VGPR (n = 10) and PR (n = 15). Two patients achieved a MR while 6 patients had SD, resulting in a clinical benefit rate of 100%. The ORR was 70% among the 23 patients with previous exposure to lenalidomide and bortezomib, and among the 10 patients who were considered refractory to lenalidomide . Based on these encouraging data, BT-062 in combination with lenalidomide or pomalidomide and dexamethasone (NCT01638936) was investigated in an ongoing, prospective, open-label, multicentre, phase I/IIa study in patients with RRMM. BT062 100 mg/m 2 was administered on days 1, 8
and 15 in a 4-week cycle in combination with dexamethasone (20-40 mg on days 1, 8, 15 and 22) and lenalidomide (25 mg, daily on days 1-21) or pomalidomide (4 mg, daily on days 1-21). Overall, 38 patients received BT062/lenalidomide/dexamethasone and an additional 17 patients were treated with BT062/pomalidomide/dexamethasone. Similar to the prior studies, 90% of AEs were grade 1 or 2, the most common being diarrhoea, fatigue and nausea. Of the 43 evaluable patients, the ORR was 77%. The median duration of response (DOR) was 21Á0 months. The ORR among the 17 patients who were treated with BT062/pomalidomide/dexamethasone was 79% (VGPR: 4, PR: 7), all of which had prior exposures to both lenalidomide and bortezomib and progressed on their last therapy (Kelly et al, 2016) .
Anti-IL6
IL6 is produced by the stromal cells within the bone marrow and plays a crucial role in the proliferation and survival of MM cells (Klein et al, 1989) . IL6 is implicated in chemotherapy-resistance by its ability to protect against cell death by regulating the activity of anti-apoptotic heat shock proteins (Voorhees et al, 2007) .
Siltuximab
Siltuxmab is a chimeric mAb targeting IL6. Preclinical studies were encouraging with synergistic cytotoxic activity when siltuximab was combined with other agents such as bortezomib (Voorhees et al, 2007 (Voorhees et al, , 2009 . A Phase I, dose-escalating study was conducted using siltuximab as a single agent in RRMM patients. Although the drug was well tolerated, no responses were recorded (van Zaanen et al, 1998) . A Phase II trial evaluated siltuximab as a single agent as well as in combination with dexamethasone (Voorhees et al, 2013) . As monotherapy, 62% of patients achieved SD but when administered with dexamethasone, the PR rate was 19% and MR rate was 28% in this heavily pretreated population. Infections of any grade were seen in 57% of patients; grade 3 and 4 in 12% and 6% of patients, respectively (Table I) (Voorhees et al, 2013) .
A Phase II, randomized study of bortezomib, melphalan and prednisone (VMP) with or without siltuximab was completed. One-hundred-and-six patients were randomized to receive either VMP alone or VMP combined with siltuximab (11 mg/kg every 3 weeks) followed by siltuximab maintenance. The ORR for the siltuximab group was 88% versus 80% in the VMP alone group. The CR rate was 27% and 22%, respectively. Median PFS and OS at 1 year were identical in both arms. The authors concluded that the addition of siltuximab to VMP did not significantly improve outcomes or response rates (San-Miguel et al, 2014) .
Anti-B cell activating factor (BAFF)
B cell activating factor (BAFF, also termed TNFSF13B) is part of the bone marrow microenvironment; it is produced by monocytes, osteoclasts and neutrophils (Moreaux et al, 2005) . BAFF binds to tumour necrosis-factor (TNF)-related receptors, which activate several pathways that contribute to the survival of MM cells and play a role in dexamethasone resistance (Moreaux et al, 2004; Tai et al, 2006; Neri et al, 2007) .
Tabalumab
Tabalumab is a humanized mAb targeting serum and membrane-bound BAFF. In vitro studies demonstrated antitumoural activity (Neri et al, 2007) .
A Phase I trial investigating the safety of tabalumab in combination with bortezomib and dexamethasone in RRMM patients was recently published (Raje et al, 2016a) . Fortyeight patients were enrolled: 20 to the dose-escalation arm and 28 to the expansion arm, in which 100 mg of tabalumab (once every 3 weeks) in combination with 1Á3 mg/m 2 of bortezomib (days 1, 4, 8 and 11) was evaluated. All 48 patients had received at least one prior therapy with either bortezomib (77%) or an IMiD (88%). The ORR was 42%; 3 patients achieved a CR, 2 achieved a VGPR and 15 achieved a PR. Responses were more frequent in patients with baseline BAFF levels < 1500 pg/ml. The common grade 3-4 AE's were thrombocytopenia, pneumonia and neuropathy. Most patients discontinued treatment for progressive disease (n = 35, 73%). Median DOR and median time to progression were 7Á2 and 4Á8 months, respectively. Overall, the response rate of 42% is somewhat lower than one might expect compared to other combination regimens among patients with RRMM (Table I) (Raje et al, 2016a) . In a Phase II, double-blinded study, 220 patients with RRMM were randomly assigned to dexamethasone 20 mg and bortezomib 1Á3 mg/m 2 in combination with placebo (n = 72), tabalumab 100 mg (n = 74), or tabalumab 300 mg (n = 74). There were no significant differences in median PFS among the three cohorts. When stratified for BAFF expression, patients with low baseline levels (n = 162) had significantly longer median PFS than those with high BAFF expression (n = 55) (8Á3 versus 5Á8 months, P = 0Á015). The treatment-emergent AEs were thrombocytopenia (37%), fatigue (37%), diarrhoea (35%) and constipation (32%). Overall, PFS was not improved with the addition of tabalumab compared to placebo, even at higher doses (Raje et al, 2017a) .
Anti-receptor activator of nuclear factor (NF)-jB ligand (RANKL)
Receptor activator of NF-jB ligand (RANKL, also termed TNFSF11) plays a key role in the pathophysiology of bone disease in MM by activating osteoclasts and promoting osteoclastogenesis (Yaccoby et al, 2002 (Yaccoby et al, , 2004 .
Denosumab
Denosumab is a humanized mAb that targets RANKL. Although none of the trials looking at single agent denosumab demonstrated any reduction in monoclonal protein, there was a decrease in bone resorption that persisted up to 84 days after a single dose (Body et al, 2006) . In a randomized, double-blind, international Phase III study (Henry et al, 2011) comparing denosumab with zoledronic acid (ZA) in patients with advanced solids cancers or MM, denosumab was non-inferior to ZA in delaying time to first skeletal event. Although OS and disease progression were similar in both arms, an ad hoc OS analysis of the MM subset of patients (n = 180) favoured the ZA cohort (95% confidence interval (CI) 1Á13-4Á50, P = 0Á014). Hypocalcaemia was seen more often in the denosumab group. Although rates of AEs and serious AEs (including osteonecrosis of the jaw) were not different between the two compounds, ZA lead to more renal events. Unfortunately, this study suffered from imbalances with respect to baseline characteristics between groups, as well as a large number of patients who were lost to follow-up (Raje et al, 2016b) . Survival analysis will be better assessed in an ongoing, phase III, randomized, double-blinded, multicentre study comparing denosumab to ZA in subjects with newly diagnosed MM (NCT01345019). Preliminary data was presented at the American Society of Clinical Oncology (ASCO) in June 2017, demonstrating that denosumab was non-inferior to ZA in delaying the time to first on-study skeletal-related event (HR = 0Á98, P = 0Á01) (Raje et al, 2017b) . The study demonstrated that patients randomized to receive denosumab had a significantly lower rate of renal adverse events compared to ZA (10% vs. 17Á1%, P < 0Á001). Denosumab, which is not cleared by the kidney, may offer a safe alternative for patients with MM (Raje et al, 2017b) .
Dickkopf 1 (DKK1)
DKK1 is a soluble antagonist of the WNT pathway that is overexpressed by plasma cells in patients with osteolytic lesions. The overexpression of DKK1 blocks the differentiation of osteoblasts and thus, inhibits the formation of bone (Tian et al, 2003) .
BHQ880
BHQ880 is a fully human neutralizing antibody targeting DKK1. Preclinical studies have demonstrated that BHQ880 reduces IL6 secretion and tumour growth, as well as promoting osteoblastogenesis in both in vitro and mouse models . A Phase Ib open-label, multicentre, single-arm study was designed to determine the MTD and the DLT of escalating doses of BHQ880 in combination with anti-myeloma therapy and ZA in patients with RRMM (Iyer et al, 2014) . Twenty-eight patients were administered BHQ880 at doses of 3-40 mg/kg. Although no DLTs were reported and thus no MTD determined, the recommended Phase II dose was declared to be 10 mg/kg. There was a trend towards increased bone density over time; specifically, in the spine from cycle 12 and onwards in some patients (Iyer et al, 2014) . Only a small number of patients experienced an increase in the number or size of lytic bone lesions.
Five new skeletal-related events (SREs) occurred in four patients, but it is believed that three of these were considered to be a progression of baseline SREs. The main limitation of this study is the difficulty in interpreting the cause and effect because of the concomitant use of ZA and anti-MM therapy in conjunction with BHQ880.
A study looking at BHQ880 as a single agent in patients with smouldering MM has been completed . Twenty-five patients were enrolled. No grade 3/4 AEs or serious AEs were observed. The most common AEs, were arthralgia (16%), fatigue (12%), pyrexia (12%), extremity pain (12%) and upper respiratory tract infection (12%). There was preliminary evidence of anabolic bone activity among 4 of the 5 patients evaluated based on quantitative computed tomography (qCT) and finite element analysis (FEA). Of note, BHQ880 did not demonstrate any anti-MM activity .
PD-1/PD-L1 antibodies and check point inhibition
PD-1 (also termed PDCD1) is a member of the CD28 family of receptors (Ishida et al, 1992) and is expressed on the surface of antigen-activated T cells (Keir et al, 2007) . PD-1 has two ligands: PD-L1(CD274) and PD-L2 (PDCD1LG2). PD-L1 is expressed on antigen presenting cells and on various non-haematopoietic cells (Yamazaki et al, 2002) . PD-1 acts by limiting T cell activation and thus, when bound to PD-L1, it delivers an inhibitory signal resulting in the reduced production of cytokines and T cell proliferation (Freeman et al, 2000) . Ultimately, PD-1 plays a role in the maintenance of self-tolerance by suppressing the activation of autoreactive T cells (Keir et al, 2008) .
PD-L1 is aberrantly expressed on a wide array of solid tumours (Dong et al, 2002) but not present on normal epithelial cells. Various studies have shown that PD-L1 is absent on normal plasma cells (Liu et al, 2007) but expressed on tumour cells from patients with MM (Benson et al, 2010; Kuranda et al, 2010) . Studies demonstrated that the PD-1/PD L1 interaction promotes progression of MM by inhibiting the immune system's ability to control the disease (immune escape) (Rosenblatt et al, 2011; Tamura et al, 2013) . In addition, the degree of PD-L1 expression was associated with disease progression. It has also been demonstrated that T cells isolated from patients with MM demonstrate PD-1 expression (Rosenblatt et al, 2011) . Ray et al (2015) confirmed that PD-L1 is not only highly expressed on MM cells, but also on MM patient-derived plasmacytoid dendritic cells (pDCs) within the bone marrow, both of which suppress PD-1-expressing T cell and NK cell immune function. The blockade of the PD-L1-PD-1 signalling axis via an anti-PD-L1 antibody enhanced CD8+ cytotoxic T lymphocyte and NK cell-mediated cytolytic activity (Ray et al, 2015) . Benson et al (2010) also established that NK cells from myeloma patients expressed PD-1 as opposed to NK cells from healthy individuals. When a PD-1 mAb was applied, there was observed enhancement of the cytolytic activity of NK cells against MM cells demonstrated that the administration of an anti-PD-L1 antibody managed to suppress myeloma progression in mice. In another study evaluated the impact of single and dual blockade of PD-1/PD-L1, alone or in combination with lenalidomide, on immune cell function and the growth of MM cell growth in the bone marrow milieu (Gorgun et al, 2015) . This study demonstrated that the anti-MM immune response was enhanced by the addition of lenalidomide providing rationale for the combination of PD-1/PD-L1 blockade agents with an immunomodulator in future clinical studies (Gorgun et al, 2015) .
MK-3475

Pembrolizumab (MK-3475)
MK-3475 is a potent, selective, humanized IgG4 anti-PD-1 mAb aimed at blocking the interaction between PD-1 with PD-L1 and PD-L2 with the hope of attaining tumour regression. KEYNOTE-023 (NCT02036502) is an open-label, Phase I, multicentre, non-randomized, dose-escalation trial looking to evaluate the safety and tolerability of MK-3475 when combined with lenalidomide and dexamethasone in patients with RRMM (at least 2 prior lines of therapy including PI and IMiD). Preliminary data was presented at the American Society of Clinical Oncology annual meeting in 2016 (Mateos et al, 2016) . Enrolled patients received 2 mg/kg of pembrolizumab every 2 weeks in combination with 10 mg or 25 mg of lenalidomide on days 1-21 (out of a 28-day cycle) and weekly dexamethasone. The MTD was defined as pembrolizumab 200 mg fixed dose in combination with lenalidomide 25 mg and dexamethasone 40 mg in the expansion cohort. As of September 2015, 33 additional patients were enrolled onto the dose-expansion phase. Thirty-six patients (72%) experienced at least one AE of any grade, most commonly thrombocytopenia (28%) and neutropenia (24%). After a median follow-up of 9Á7 months, 13/17 (76%) patients in the dose determination phase responded to treatment: 4 VGPRs and 9 PRs. Of note, these responses were also observed among patients with immunomodulator-refractory and double-refractory myeloma (Table I) (Mateos et al, 2016) .
In a Phase II study, pembrolizumab (200 mg IV every 2 weeks), pomalidomide (4 mg on days 1-21) and dexamethasone (40 mg weekly) demonstrated clinical activity in patients with RRMM who were pomalidomide-na€ ıve (90% lenalidomide refractory) with a response rate of 60% [sCR (6%), CR (2%), VGPR (19%), PR (33%)]. The median PFS was 17 months. The ORR seemed to correlate with PD-1 expression on myeloma cells by immunohistochemistry. TEAEs of any grade occurred in 73% of patients. The most Pcommon non-haematological AEs were fatigue, hyperglycaemia, dizziness and constipation. One-third of patients experienced respiratory symptoms [dyspnea (31%), upper respiratory tract infection (URTI; 33%), pneumonia (21%) and influenza A (8%)]. The most common immunemediated events included pneumonitis (13%), hypothyroidism (10%), adrenal insufficiency (4%) and hepatitis (4%). There was a 42% incidence of grade 3 neutropenia associated with increased risk of infection. One patient died of neutropenia and sepsis. Although the combination of pembrolizumab and pomalidomide resulted in significant clinical activity, there were higher-than-expected rates of infection and autoimmunity (Table I) (Badros et al, 2017) .
These promising results have led to KEYNOTE-185 (NCT02579863) and KEYNOTE-183 (NCT02576977), both phase III studies administering pembrolizumab (200 mg every 3 weeks) or placebo in combination with lenalidomide (KEYNOTE-185) or pomalidomide (KEYNOTE-183) and low dose dexamethasone (40 mg weekly) in newly diagnosed MM and RRMM, respectively. In KEYNOTE-183 (n = 249), 29 deaths were reported in the pembrolizumab arm versus 21 deaths in the control arm. The hazard ratio for OS was 1Á61 (95% CI, 0Á91-2Á85), translating into more than a 50% increase in the relative risk of death in the pembrolizumab arm. In KEYNOTE-185 (N = 301), at a median follow-up of 6Á6 months, there were 19 deaths in the pembrolizumab group compared with 9 in the control arm.
As of June 2017, the FDA placed a full clinical hold on these three studies (KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023) based upon an increased risk of death among patients treated with pembrolizumab in 2 of these 3 trials. The reason for death rate imbalance in the pembrolizumab arms can only be speculated until safety data is publicly released.
BMS-936558
Nivolumab (BMS-936558)
PNivolumab is an anti-PD-1 mAb that has shown significant therapeutic activity and an acceptable safety profile in patients with relapsed or refractory Hodgkin lymphoma. In a Phase I open-label, dose-escalation study, patients with various relapsed or refractory haematological malignancies, including B and T cell lymphomas and MM, received nivolumab at doses of 1 or 3 mg/kg every 2 weeks (Lesokhin et al, 2016) . Twenty-seven patients with RRMM took part in this study, 24 of whom experienced disease progression after prior IMiD and PI therapy. Because the MTD was not reached, patients in the expansion phase received nivolumab at a dose of 3 mg/kg. Ninety-six percent of patients experienced at least one AE, of which 18% were considered grade 3. Only one patient experienced a grade 5 AE. Immune reactions due to T-cell activation were observed in 34% of patients (predominantly grade 1 or 2). Nine patients developed pneumonitis, including one fatal case. Among the patients with MM, SD was the best response in 17 out of 27 patients which lasted a median of 11Á4 weeks (Table I) (Lesokhin et al, 2016) . Overall, there was a lack of objective tumour response in this study among RRMM patients when compared to the other participants. The reason for this poor response remains unclear but it has been theorized that it CheckMate-602 (NCT02726581) is a phase III trial evaluating the combination of nivolumab, elotuzumab, pomalidomide and dexamethasone in patients with RRMM. CheckMate-039 (NCT01592370) is a phase I study investigating the safety of nivolumab in combination with daratumumab, with or without pomalidomide and dexamethasone in the relapsed/refractory population. CA204142 (NCT02612779) is a phase II study assessing the safety and efficacy of elotuzumab with pomalidomide and dexamethasone versus elotuzumab with nivolumab for lenalidomiderefractory patients. The FDA has placed partial clinical holds on these 3 clinical trials based on the safety concerns identified in clinical trials combining pembrolizumab with immunomodulatory agents.
Durvalumab
PDurvalumab is an IgG kappa1 human mAb that inhibits binding of PD-L1 to PD-1 (Stewart et al, 2015) ; it has been granted accelerated approval for locally advanced or metastatic urothelial carcinoma and was recently granted breakthrough therapy designation for patients with locally advanced unresectable non-small cell lung cancer. The FDA has placed partial clinical holds on trials assessing durvalumab in combination with Daratumumab (NCT02807454, NCT03000452), and in a phase 1b study alone or in combination with pomalidomide with or without dexamethasone (NCT02616640) in RRMM. In newly diagnosed patients, a study combining durvalumab with lenalidomide with or without dexamethasone (NCT02685826) has been placed on a full clinical hold. Patients already enrolled in the partially held trials may continue treatment if they have experienced a clinical benefit, but no new patients are being enrolled. Furthermore, treatment has been stopped completely for patients enrolled in the trial on full clinical hold.
T cell approaches
B cell maturation antigen (BCMA)
BCMA (also termed TNFRSF17) is an antigen that plays a key role in the regulation and differentiation of B cells into plasma cells (Carpenter et al, 2013) . BCMA is expressed homogeneously on the surface of plasma cells in patients with MM, plasma cell leukaemia and plasmacytomas. The expression of BCMA on plasma cells was confirmed using gene expression profiling and flow cytometry. BCMA expression was observed in clonal plasma cells from 723 out of 726 (99Á5%) patients with MGUS and MM, but was absent on normal bone marrow cells (Seckinger et al, 2015) . Tai et al (2016) demonstrated that overexpression or activation of BCMA by a proliferation-inducing ligand (APRIL [TNFSF13]) promoted augmented MM cell growth and survival as well as the in vivo growth of xenografted MM cells harbouring a Tp53 mutation in mice. The inhibition of APRIL by an antagonistic anti-APRIL mAb successfully prevented in vivo MM cell growth (Tai et al, 2016) .
A mAb that effectively targets BCMA has yet to be discovered. Tai et al (2014) demonstrated that BCMA was successfully targeted by J6M0-mcMMAF (GSK2857916), a novel humanized and afucosylated antagonistic anti-BCMA antibody-drug conjugate, via a non-cleavable linker. J6M0-mcMMAF effectively exerted its anti-MM effect via ADCC, which was further enhanced by the addition of lenalidomide. Furthermore, J6M0-mcMMAF induced ADCP via the recruitment of macrophages. Together, these results demonstrate that GSK2857916 is a promising next-generation immunotherapeutic agent in MM (Tai et al, 2014) .
Chimeric antigen receptors (CAR) T cell in MM
PChimeric antigen receptors (CAR) are synthetic fusion proteins made up of the variable portion of an antibody that targets a surface antigen expressed on a tumour cell. The synthetic gene is genetically incorporated into the T cell using retroviral or lentiviral vectors leading to constitutive expression. CAR T cells targeting CD19 have been the most successful and the most widely studied to date (Sadelain, 2015) . CD19 is a surface protein expressed on precursor and mature B cells and thus, is a target of interest in disease like acute B cell lymphoblastic leukaemia and non-Hodgkin lymphoma. Clonal plasma cells do not routinely express CD19 on their surface. BCMA is an ideal target for CAR T cells in MM as it is highly expressed on the surface of clonal plasma cells (Carpenter et al, 2013) .
Results from a first-in-human Phase I clinical trial at the National Cancer Institute using CAR-BCMA in RRMM patients (NCT02215967) was recently published (Ali et al, 2016;  (Table II) . Participants in this study had advanced MM (median of 7 previous lines of therapy) and they had to demonstrate >50% BCMA expression by flow cytometry or immunohistochemistry Twelve patients were treated in this dose-escalation trial with CAR-BCMA following 3 days of treatment with 300 mg/m 2 of cyclophosphamide and 30 mg/ m 2 of fludarabine. One of four doses of CAR+ T cells/kg were used: 0Á3 9 10 6 , 1 9 10 6 , 3 9 10 6 , and 9 9 10 6 . Of the 6 patients who received the two lowest doses of CAR+ T cells, one achieved a PR (duration of response: 2 weeks) while the rest had SD. On the 3rd dose level, one patient achieved a VGPR with a negative positron emission tomography (PET) scan. Three patients were treated at the highest dose level (9 9 10 6 CAR+ T cells/kg): one patient, who had 90% bone marrow plasmacytosis, achieved a sCR that lasted for 17 weeks before relapse and the second patient, who had 80% bone marrow plasma cell involvement, had undetectable plasma cells on a repeat bone marrow biopsy 4 weeks following treatment. Twenty-eight weeks after the infusion, this patient's bone marrow plasma cells were undetectable by flow cytometry. Of note, the patients with the most impressive anti-myeloma responses also had the highest IL6 levels following treatment. Patients who responded demonstrated lower BCMA levels after CART+ T cell exposure. A dose of 9 9 10 6 was associated with grade 3-4 cytokine release syndrome (fever, tachycardia, dyspnoea, acute kidney injury, hypotension and muscle damage) in the responding patients. Most recently, four other CAR-BCMA clinical trials in RRMM have opened (Table II) . The University of Pennsylvania is conducting a phase 1, dose-escalating trial (NCT02546167), in patients with RRMM. Patients are receiving CAR-BCMA cells as split-dose infusions. In this trial, the expression of BCMA is not required for eligibility. The first cohort is receiving CAR-BCMA T cells alone without conditioning chemotherapy. The other cohorts will receive cyclophosphamide and varying doses of CAR T cells. To date, 6 patients (all IMiD/PI-refractory with a median of 9 prior lines of therapy) have been treated in Cohort 1. Cytokine release syndrome occurred in 5 patients; 2 with grade 3 reactions requiring tocilizumab. There was one DLT: grade 4 posterior reversible encephalopathy syndrome in one patient. Other grade 3/4 toxicities included hypophosphataemia (n = 3), hypocalcaemia (n = 2), anaemia, neutropenia, thrombocytopenia, fatigue, infection, hypertension and pleural effusion (n = 1 each). The first enrolled patient has ongoing sCR for more than 12 months with minimal residual disease-negative bone marrow by flow cytometry. Patient 3, who originally had pleural involvement, achieved a VGPR with complete resolution of extramedullary disease on PET/ computed tomography scan. The patient later progressed at 5 months and this was associated with a significant reduction of CART-BCMA cells and loss of BCMA expression on MM cells by flow cytometry .
Resistance to CAR-BCMA T cells has become an area of interested as its mechanism is not entirely understood. It also remains to be seen if extent of BCMA expression predicts degree of response.
Future directions
With the success of daratumumab, CAR-CD38 T cells are now in pre-clinical trials. Donor-derived CAR T cells may also be a promising therapeutic avenue, combining the concept of targeted therapy with allogeneic SCT. The use of donor-derived CAR T cells may reduce the risk of graft-versus-host disease (GVHD) by limiting the number of GVHDcausing donor T cells, though it will probably lead to more toxicities than what has been reported with autologous CAR T cells.
Conclusion
With the approval of multiple new agents over the last decade together with better supportive care, there has been a dramatic increase in the proportion of myeloma patients living longer from time of diagnosis, but a large number still develop resistance to therapy, including IMiDs and PIs. Immune therapy incorporating mAbs provide a new class of agents that offer significant promise in the treatment of MM, and especially in the relapsed and refractory setting. MAbs are not only generally well-tolerated, but they have demonstrated meaningful clinical activity, independent of baseline cytogenetic risk, age and SCT status. Whilst most of these antibodies exhibit single agent activity, clinical trials combining these agents with IMiDs and PIs have resulted in promising outcomes across almost all subgroups.
There are still many unanswered questions surrounding the proper use of mAbs and when to incorporate them into the treatment algorithm. For instance, less is known about the role of mAbs in the upfront setting, in the peritransplant period, or in precursor states such as MGUS or smouldering MM. Ongoing clinical trials are designed to address these important concerns. As we continue to develop newer mAbs targeting independent pathways, future studies will be aimed at determining the best drug combinations and how to incorporate these agents into current therapeutic paradigms with the goal of achieving better disease control and longer survival.
Immune therapies provide a highly promising and unique platform for future progress. The advent of cellular therapy, and CAR-T treatment in particular, offers a new approach to restoring targeted host immunity. Combined with the real excitement engendered by check point inhibition, recent safety concerns notwithstanding, these advances altogether provide real hope for continued improvement in patient outcomes with lasting disease control, and particular benefit anticipated in the management of early onset disease.
